共 50 条
- [41] Safety, Tolerability, and Pharmacokinetics of RT234 (Vardenafil Inhalation Powder): A First-in-Human, Ascending Single- and Multiple-Dose Study in Healthy SubjectsJOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2021, 34 (04) : 251 - 261Eldon, Michael A.Parsley, Edwin L.Maurer, MariTarara, Thomas E.Okikawa, JerryWeers, Jeffry G.
- [42] First-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending doses clinical study to assess the safety, tolerability, and pharmacokinetics of cipargamin administered intravenously in healthy adultsANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (09)Venishetty, Vinay KumarLecot, JeanNguyen, AmandaZhang, JiePrince, William T.
- [43] The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitisBRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (12) : 2507 - 2518Nnane, IvoFrederick, BartYao, ZhenlingRaible, DonaldShu, CathyeBadorrek, Philippvan den Boer, MaartenBranigan, PatrickDuffy, KarenBaribaud, FredericFink, DamienYang, Tong-YuanXu, Zhenhua
- [44] A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of a First-in-Human Engineered Cationic Peptide, PLG0206, Intravenously Administered in Healthy SubjectsANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (01)Huang, DavidDobbins, DespinaGhahramani, ParvizFriedland, IanSteckbeck, Jonathan
- [45] Safety, tolerability, and pharmacokinetics of JX11502MA in Chinese healthy subjects: a first-in-human, randomized, double-blind, placebo-controlled study following single-dose administrationEXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (01) : 51 - 61Yu, YiminHe, JingjingHuang, ZhiweiLi, YanWu, YingShen, YifengZhou, YanlingBao, CungangJin, ZhipingLi, Huafang
- [46] Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid fc-fused interleukin-1 receptor antagonist, in healthy subjects: A first-in-human studyBRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (02) : 372 - 379Oh, JaeseongHuh, Ki YoungCho, Young-GyuCha, Ji-EunKim, Se-JinYoon, Seo HyunPark, Sung SupYoon, HyunyeeLee, JieonLee, Howard
- [47] First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinomaCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (06) : 1057 - 1063Massard, ChristopheSoria, Jean-CharlesKrauss, JuergenGordon, MichaelLockhart, Albert CraigRasmussen, ErikUpreti, Vijay V.Patel, SonalNgarmchamnanrith, GatareeHenary, Haby
- [48] First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinomaCancer Chemotherapy and Pharmacology, 2019, 83 : 1057 - 1063Christophe MassardJean-Charles SoriaJürgen KraussMichael GordonAlbert Craig LockhartErik RasmussenVijay V. UpretiSonal PatelGataree NgarmchamnanrithHaby Henary
- [49] Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled studyJOURNAL OF DERMATOLOGY, 2018, 45 (09) : 1053 - 1062Ohtsuki, MamitaroKubo, HiroshiMorishima, HitomiGoto, RyosukeZheng, RichuanNakagawa, Hidemi
- [50] First-in-Human, Single- and Multiple-Ascending-Dose, Food-Effect, and Absolute Bioavailability Trials to Assess the Pharmacokinetics, Safety, and Tolerability of Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor Against Herpes Simplex Virus in Healthy SubjectsCLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (07): : 749 - 760Kropeit, DirkBonsmann, Susannevon Richter, OliverMcCormick, DavidPausch, JorgSumner, MelanieBirkmann, AlexanderZimmermann, HolgerRuebsamen-Schaeff, Helga